TONIX PHARMACEUTICALS HOLDIN(NASDAQ:TNXP) stock News

TNXP Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill - Mentions: IRWD CASI ADAP TPIC ...

Wondering what's happening in today's after-hours session?

4 days ago - By: Chartmill - Mentions: TRIB GEVO KODK TPIC ...

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

a day ago - By: Benzinga - Mentions: TRIB CASI ADAP PPCB ...

12 Health Care Stocks Moving In Friday's After-Market Session

a day ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

2 days ago - By: Benzinga - Mentions: ATNF VMAR AMAT GAMB ...

Why KULR Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

5 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock News

TNXP Latest News, Press Relases and Analysis

Wondering what's happening in today's after-hours session?

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

12 Health Care Stocks Moving In Friday's After-Market Session

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Why KULR Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025